The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XX.b

Opportunistic pulmonary/systemic infections

Publications

Gastaldi R, Sicaud A, Gaudin P, Baillet A

Pulmonary Pasteurellosis in a Patient Treated With Tocilizumab for Rheumatoid Arthritis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2017 Dec;23;451-452 — 2017 Dec — 451-452

Keyser FD

Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.

Current rheumatology reviews 2011 Feb;7;77-87 — 2011 Feb — 77-87

Hoshi D, Nakajima A, Inoue E, Shidara K, Sato E, Kitahama M, Seto Y, Tanaka E, Urano W, Ichikawa N, Koseki Y, Momohara S, Taniguchi A, Nishimoto N, Yamanaka H

Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab.

Modern rheumatology 2012 Feb;22;122-7 — 2012 Feb — 122-7